ArticleFrontiers in medicine2026
Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD), is today the leading cause of chronic liver conditions in the context of a global epidemic of obesity and metabolic disorders. Our study aims to determine the prevalence of MASLD and advanced liver fibrosis as well as the associated factors in patients with type 2 diabetes Mellitus (T2D). Methods: Cross-sectional study including 149 patients with T2D, conducted in the Endocrinology-Diabetology and Hepato-Gastroenterology departments over a period of 6 months. Screening for steatosis and liver fibrosis was carried out using FibroScan. Results: The average age of the patients was 57.9 ± 11.8 years, with a female predominance (63.8%). Based on the EASL cutoffs, the MASLD ratio was 69.1% [95% CI (61.7-76.5], Conclusion: In our study, we found that 69.1% of participants met the criteria for MASLD, and advanced fibrosis could not be ruled out in 17.4% of patients, with 4% being at high risk (≥12 kPa). It is essential to identify these at-risk patients who require multidisciplinary management in order to prevent progression to cirrhosis and its complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.